In many cases, an excess of IL-17 is associated with abnormal inflammation, implicated in rheumatoid arthritis, asthma, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus and autoimmune encephalomyelopathy, which, not surprisingly, have become a major therapeutic target for these diseases. This evidence concerns the gene IL17A and asthma.